RxDoctor Payments Data

Nafeesa Siddiqui, MD

Psychiatry · Wayne, NJNPI 1225107121

Payments from drug & device makers

$953in general payments, 2019–2025

Across 63 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$149
  • Alkermes, Inc.$144
  • Vanda Pharmaceuticals Inc.$125
  • E.r. Squibb & Sons, L.L.C.$122
  • Sunovion Pharmaceuticals Inc.$112
  • AbbVie$82
  • plus $219 from 5 others

What the payments were for

  • Food & beverage$953100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$953 in reported general payments places this provider in the 70th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$6,717
Medicare patients
26
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl30$40,883
Clozapine66$8,273
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl49$3,707
Oxcarbazepine74$3,440
Clozapine OdtClozapine12$2,531
Asenapine Maleate12$2,135
Alprazolam152$2,085
Depakote ErDivalproex Sodium11$1,993
Quetiapine Fumarate84$1,231
Doxepin Hcl26$1,136
Aripiprazole31$1,060
Bupropion XlBupropion Hcl49$1,027
Ziprasidone Hcl15$915
Clonazepam54$692
Divalproex Sodium23$688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$82$40,88330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in Wayne

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →